Whole-body imaging of oncologic patients using 16-channel PET-CT

K. U. Juergens; M. L. Oei; M. Weckesser; C. Franzius; D. Wormanns; O. Schober; W. Heindel

doi:10.3413/nukmed-0105

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2008; 47(01): 30-36
DOI: 10.3413/nukmed-0105

Originalarbeiten

Schattauer GmbH

Whole-body imaging of oncologic patients using 16-channel PET-CT

Evaluation of an IV contrast enhanced MDCT protocolGanzkörper-Bildgebung bei onkologischen Patienten mittels 16-Zeilen-PET-CTBewertung eines optimierten Kontrastmittel-gestützten CT-Protokolls

Authors

K. U. Juergens^*

¹Departments of Clinical Radiology
M. L. Oei^*

¹Departments of Clinical Radiology
M. Weckesser

²Departments of Nuclear Medicine, University of Muenster
C. Franzius

²Departments of Nuclear Medicine, University of Muenster
D. Wormanns

¹Departments of Clinical Radiology

³Departments of Evangelic Chest Hospital, Berlin, Germany
O. Schober

²Departments of Nuclear Medicine, University of Muenster
W. Heindel

¹Departments of Clinical Radiology

Abstract

Summary

Aim: This study evaluated a MDCT protocol for contrast-enhanced 16-channel PET-CT with regard to scan range and duration of a whole-body ¹⁸F-FDG PET-CT examination, the occurrence of contrast-material induced artefacts and quantitative assessment of CT attenuation. Patients, methods: 205 patients (51.9 ± 12.4 years) with different malignant tumours underwent whole-body PET-CT; the study protocol had been approved by the institutional review board. Contrast-enhanced MDCT (16 ˟ 1.5 mm; 120 ml Iomeprol 3 ml/s, 50 ml saline chaser bolus, scan delay 70 s; oral contrast) was also used for attenuation correction. From MDCT data mean scan range and duration, occurrence of contrast media-induced artefacts, and mean CT densities of jugular (jv) and subclavian (scv), superior (vcs) and inferior (vci) caval, portal (pv), and bilateral external iliac veins, pulmonary (ap) and iliac arteries, descending thoracic and abdominal aorta, all cardiac chambers, as well as both liver lobes, spleen, adrenal glands and kidneys were determined. Results: Attenuation corrected PET images were free of contrast media-related image artefacts. Homogeneous contrast enhancement was found in the mediastinal veins (right/left jv 171 ± 34/171 ± 35, scv 127 ± 50/127 ± 40, vcs 153 ± 36 HU) and arteries (e.g. ap 145 ± 26/151 ± 26). Cardiac chambers, abdominal vessels (e.g. vci 138 ± 24, pv 159 ± 25 HU), and parenchymal organs revealed sufficient and homogenous contrast-enhancement in all cases. No beam-hardening artefacts occurred in the neighbourhood of the subclavian veins. Conclusion: The chosen whole-body ¹⁸F-FDG 16-slice PET-CT protocol allowed for craniocaudal CT scanning with high vessel and parenchymal contrast revealing no IV contrast-media induced artefacts in attenuation-corrected PET data sets.

Zusammenfassung

Ganzkörper-Untersuchungen durch ¹⁸F-FDG-PET-CT erfordern die Anpassung der für Mehrzeilen-Spiral-CT etablierten Untersuchungsprotokolle. Ziel dieser Studie war die Evaluation eines optimierten Kontrastmittel (KM)-gestützten CT-Protokolls für die hochauflösende 16-Zeilen-PET-CT des Ganzkörpers. Patienten, Methoden: 205 Patienten (51,9 ± 12,4 Jahre) erhielten im Rahmen ihres Tumorstagings eine ¹⁸F-FDG-PET-CT des Ganzkörpers (Biograph Sensation 16, Siemens: 16 ˟ 1,5 mm; 120 ml KM 3 ml/s; Scandelay 70 s; FDG 4 MBq/kg KG). Mittels ROI-Technik wurden Dauer/Länge des CT-Scans, Auftreten von KM-induzierten Artefakten, mittlere CT-Dichtewerte [HU] in den Vv. jugulares int., subcl. (scv), cava sup. (svc) und inf. (ivc), porta (pv) und iliacae ext., den Aa. pulmonales (pa), der Aorta thoracalis desc. und abd., den Herzhöhlen, bd. Leberlappen, Milz, Nebennieren, Nieren und Aa. iliacae ext. untersucht (e-soft®-Workstation). Ergebnisse: Die Ganzkörper-PET-CT-Untersuchungen wiesen hohe diagnostische Qualität auf (CT-Scandauer 15,3 ± 2,1 s). Ein homogenes KM-Enhancement wiesen Jugularvenen (re./Ii. 171 ± 34/171 ± 35 HU), mediastinale Venen (scv re./li. 127 ± 50/127 ± 41 HU; svc 153 ± 36 HU) und Arterien (pa re./li. 145 ± 26/151 ± 26 HU) und Herzhöhlen (z. B. RA 149 ± 25 HU) auf (max. Dichte re./li. scv 279/277 HU bzw. vcs 235 HU). Die abdominellen Gefäße (z. B. ivc 138 ± 24, pv 159±25, aa 149 ± 25 HU) und parenchymatösen Oberbauchorgane (re. Leberlappen 106 ± 21, Milz 113 ± 17 HU) zeigten ein diagnostisch suffizientes, homogenes Enhancement ohne KM-induzierte Artefakte. Schlussfolgerung: Das gewählte PET-CT-Protokoll erlaubt eine 16-Zeilen-CT-Untersuchung des Ganzkörpers in kraniokaudaler Scanrichtung mit exzellentem Gefäß- und Parenchymkontrast ohne Induktion von KM-induzierten Artefakten in den mediastinalen Venen sowie den Schwächungskorrigierten PET-Daten.

Keywords

CT - PET-CT - tumour staging - intravenous CT contrast agent

Schlüsselwörter

CT - PET-CT - Staging - intravenöse CT-Kontrastmittel

Full Text

References

References
1 Allen-Auerbach M, Yeom K. et al. Standard PET/ CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 2006; 47: 298-301.
2 Antoch G, Freudenberg LS, Egelhof T. et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43: 1339-1342.
3 Antoch G, Saoudi N, Kuehl H. et al. Accuracy of whole-body dual-modality Fluorine-18-2-Fluoro-2-deoxy-D-Glucose positron emission tomography and computed tomography (FDG-PET/ CT) for tumour staging in solid tumours: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-4368.
4 Berthelsen AK, Holm S, Loft A. et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005; 32: 1167-1175.
5 Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002; 46: 24-34.
6 Beyer T, Antoch G, Bockisch A. et al. Optimized intravenous contrast administration for diagnostic whole-body ¹⁸F-FDG PET/CT. J Nucl Med 2005; 46: 429-435.
7 Blodgett TM, McCook BM, Federle MP. Positron emission tomography/computed tomography: protocol issues and options. Semin Nucl Med 2006; 36: 157-168.
8 Brechtel K, Klein M, Vogel M. et al. Optimized contrast-enhanced CT protocols for diagnostic whole-body ¹⁸F-FDG PET-CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006; 47: 470-476.
9 Cerfolio RJ, Bryant AS, Ohja B. et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with oesophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005; 129: 1232-1241.
10 Delbeke D, Coleman RE, Guiberteau MJ. et al. Procedure guideline for tumour imaging with ¹⁸F-FDG PET/CT. J Nucl Med 2006; 47: 885-895.
11 Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology?. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
12 Gutzeit A, Antoch G, Kühl H. et al. Unknown primary tumours: detection with dual-modality PET/ CT - initial experience. Radiology 2005; 234: 227-234.
13 Juergens KU, Weckesser M, Stegger L. et al. Tumour staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitarypulmonarynodules?. Eur Radiol 2006; 16: 1131-1137.
14 Kinahan PE, Townsend DW, Beyer T. et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25: 2046-2053.
15 Lardinois D, Weder W, Hany TF. et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
16 Martinez M-J, Bercier Y, Schwaiger M. et al. PET/ CT Biograph Sensation 16. Performance improvement using faster electronics. Nuklearmedizin 2006; 45: 126-133.
17 Mawlawi O, Erasmus JJ, Munden RF. et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. Am J Roentgenol 2006; 186: 308-319.
18 Nakamoto Y, Chin BB, Kraitchman DL. et al. Effects of non-ionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227: 817-824.
19 Oliver 3rd JH, Baron RL. Helical biphasic contrast-enhanced CT of the liver: Technique, indications, interpretation, and pitfalls. Radiology 1996; 201: 1-14.
20 Pauls S, Buck AK, Hohl K. et al. Improved noninvasive T-Staging in non-small cell lung cancer by integrated ¹⁸F-FDG PET/CT. Nuklearmedizin 2007; 46: 9-14.
21 Pöttgen C, Levegrün S, Theegarten D. et al. Value of ¹⁸F-fluoro-2-deoxy-D-glucose positronemission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.
22 Reinhardt MJ, Joe AY, Jaeger U. et al. Diagnostic performance of whole-body dual modality ¹⁸F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24: 1178-1187.
23 Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 2006; 11: 58-65.
24 Tatsumi M, Cohade C, Nakamoto Y. et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237: 1038-1045.
25 Veit P, Kühle C, Beyer T. et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/ CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006; 55: 68-73.
26 Weckesser M, Stegger L, Juergens KU. et al. Correlation between respiration-induced thoracic expansion and a shift of central structures. Eur Radiol 2006; 16: 1614-1620.
27 Yau Y-Y, Chan W-S, Tam Y-M. et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?. J Nucl Med 2005; 46: 283-291.